Electroacupuncture Modulates SPMs Metabolism and Respiratory Symptoms in Patients With Sepsis Complicating ARDS

Sponsor
Tianjin Nankai Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06006325
Collaborator
(none)
20
1
2
6.4
3.1

Study Details

Study Description

Brief Summary

In this interventional clinical trial, researchers will administer electroacupuncture versus sham electroacupuncture to sepsis patients with ARDS and collect objective outcome measures. The study will be divided into 2 groups. The EA group will receive electroacupuncture and the SHAM-EA group will receive sham electroacupuncture. The purpose of this study is to investigate the effect of electroacupuncture on the synthesis of SPMs in sepsis patients with ARDS.

Condition or Disease Intervention/Treatment Phase
  • Device: electroacupuncture treatment
  • Device: sham electroacupuncture treatment
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Care Provider, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Electroacupuncture Modulates the Metabolism of SPMs and Ameliorates Respiratory Symptoms and Inflammation in Patients With Sepsis Complicating ARDS
Anticipated Study Start Date :
Aug 20, 2023
Anticipated Primary Completion Date :
Dec 31, 2023
Anticipated Study Completion Date :
Mar 2, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Electroacupuncture (EA)

The acupoints were "Deqi", and the electroacupuncture stimulator was connected and energized.

Device: electroacupuncture treatment
Patients received acupuncture on both sides of the Zusanli (ST36) acupuncture points, and after "Deqi ", the needle was connected to an electro-acupuncture device (Hwato, Suzhou Medical ). The EA stimulation lasted for 30 min.

Sham Comparator: Sham electroacupuncture (SHAM-EA)

No "Deqi" operation was performed on non-acupuncture points, and the electroacupuncture stimulator was connected and not energized.

Device: sham electroacupuncture treatment
The participants in the SHAM-EA group performed shallow punctures at the bilateral non-acupuncture points, did not perform the "Deqi" operation, and were connected to the electroacupuncture stimulator but not energized.

Outcome Measures

Primary Outcome Measures

  1. Serum levels of Lipoxin A4 (LXA4) [Up to 7 days]

    Serum levels of LXA4 were measured in post-intervention patients and levels were compared to Day 0.

Secondary Outcome Measures

  1. LXA4 levels in BALF [Up to 7 days]

    LXA4 levels were measured in the BALF of patients after the intervention and the levels were compared to day 0.

  2. Ventilation-free days [Up to 28 days]

    The number of days the patient was alive and free of mechanical ventilation (MV)

  3. Oxygenation index [Up to 7 days]

    The ratio of arterial oxygen partial pressure (PaO2 in mmHg) to fractional inspired oxygen (FiO2 expressed as a fraction, not a percentage).

  4. Ventilator-provided positive end-expiratory pressure (PEEP) [Up to 7 days]

    Ventilator parameter

  5. plateau pressure [Up to 7 days]

    Ventilator parameter

  6. tidal volume [Up to 7 days]

    Ventilator parameter

  7. Inflammation biomarkers Inflammation levels [Up to 7 days]

    Procalcitonin (PCT), C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6)

  8. Sequential Organ-Failure Assessment (SOFA) score [Up to 7 days]

    The SOFA score is used to assess the severity and prognosis of sepsis.SOFA was based on six different scores, one for each of the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems each scored from 0 to 4 with an increasing score reflecting worsening organ dysfunction.

  9. Rate of electroacupuncture-related adverse events [Up to 28 days]

    Rate of electroacupuncture-related adverse events

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Males or females over the age of 18;

  2. Diagnosis meets SPESIS 3 criteria for sepsis;

  3. The diagnosis meets the Berlin diagnostic criteria for ARDS;

  4. ARDS was diagnosed within 48h;

  5. Capable of understanding the purpose and risk of the study;

  6. Patients or proxy must give written informed consent before any assessment is performed.

Exclusion Criteria:
  1. ARDS was diagnosed 48h later;

  2. Pregnancy, lactation or perinatal period;

  3. malignant tumor;

  4. Severe liver failure or kidney failure;

  5. Predicted mortality risk of patients within 24h>80%;

  6. Severe end-stage lung disease;

  7. ECMO patients are undergoing implementation;

  8. HIV seropositive or Syphilis seropositive;

  9. Any clinical-relevant condition that might affect study participation and/or study results;

  10. Participation in any other intervention trial;

  11. Unwillingness or inability to following the study protocol in the investigators opinion.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Tianjin Nankai Hospital Tianjin Tianjin China 300000

Sponsors and Collaborators

  • Tianjin Nankai Hospital

Investigators

  • Study Director: Jianbo Yu, MD, Tianjin Nankai Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Jianbo Yu, Prof., Tianjin Nankai Hospital
ClinicalTrials.gov Identifier:
NCT06006325
Other Study ID Numbers:
  • NKYY_YXKT_IRB_2022_023_01
First Posted:
Aug 23, 2023
Last Update Posted:
Aug 23, 2023
Last Verified:
Aug 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 23, 2023